The Risk of Venous Thromboembolism, Myocardial Infarction, and Ischemic Stroke Among Women Using the Transdermal Contraceptive System Compared With Women Using Norgestimate-containing Oral Contraceptives With 35 mcg Ethinyl Estradiol
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Ethinylestradiol/norelgestromin; Ethinylestradiol/norgestimate
- Indications Pregnancy
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 15 Jul 2016 Status changed from active, no longer recruiting to completed.
- 08 May 2007 New trial record.